3-(4-(6-Oxopiperidine-3-carboxamido)phenyl)benzo[c]isoxazole-5-carboxylic Acid

ID: ALA5178548

Chembl Id: CHEMBL5178548

PubChem CID: 168276666

Max Phase: Preclinical

Molecular Formula: C20H17N3O5

Molecular Weight: 379.37

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1CCC(C(=O)Nc2ccc(-c3onc4ccc(C(=O)O)cc34)cc2)CN1

Standard InChI:  InChI=1S/C20H17N3O5/c24-17-8-4-13(10-21-17)19(25)22-14-5-1-11(2-6-14)18-15-9-12(20(26)27)3-7-16(15)23-28-18/h1-3,5-7,9,13H,4,8,10H2,(H,21,24)(H,22,25)(H,26,27)

Standard InChI Key:  RGPILQZRDRJTRK-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5178548

    ---

Associated Targets(Human)

IP6K1 Tbio Inositol hexakisphosphate kinase 1 (80 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IP6K2 Tbio Inositol hexakisphosphate kinase 2 (79 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IP6K3 Tbio Inositol hexakisphosphate kinase 3 (42 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 379.37Molecular Weight (Monoisotopic): 379.1168AlogP: 2.66#Rotatable Bonds: 4
Polar Surface Area: 121.53Molecular Species: ACIDHBA: 5HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 3.62CX Basic pKa: CX LogP: 1.64CX LogD: -1.69
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.64Np Likeness Score: -1.04

References

1. Zhou Y, Mukherjee S, Huang D, Chakraborty M, Gu C, Zong G, Stashko MA, Pearce KH, Shears SB, Chakraborty A, Wang H, Wang X..  (2022)  Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions.,  65  (9.0): [PMID:35467861] [10.1021/acs.jmedchem.2c00220]

Source